Gilberta Giacchetti

Prof. Dr. Gilberta Giacchetti

Division of Endocrinology, Deparment of Clinical and Molecular Sciences, Azienda Ospedaliero-Universitaria delle Marche, Università Politecnica delle Marche, Via Conca 71, 60126 Ancona, Italy
orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 July 2024 in Biomolecules
Verified
Journal Article
Open access
PDF file
ESEmanuele-Salvatore Scarpa
Emanuele-Salvatore Scarpa
AAAntonella Antonelli
Antonella Antonelli
GBGiancarlo Balercia
Giancarlo Balercia
ESEmanuele Salvatore Scarpa
Emanuele Salvatore Scarpa
Filippo MaggiFilippo Maggi
Filippo Maggi
MATTEO MICUCCIMATTEO MICUCCI
MATTEO MICUCCI
Polyphenols are natural bioactives occurring in medicinal and aromatic plants and food and beverages of plant origin. Compared with conventional therapies, plant-derived phytochemicals are more affordable and accessible and have no toxic side effects. Thus, pharmaceutical research is increasingly inclined to discover and study new and innovative natural molecules for the treatment of several chronic human diseases, like type 2 diabetes mellitus (T2DM) and osteoporosis. These pathological conditions are characterized by a chronic inflammatory state and persistent oxidative stress, which are interconnected and lead to the development and worsening of these two health disorders. Oral nano delivery strategies have been used to improve the bioavailability of polyphenols and to allow these natural molecules to exert their antioxidant, anti-inflammatory, anti-diabetic, and pro-osteogenic biological activities in in vivo experimental models and in patients. Polyphenols are commonly used in the formulations of nutraceuticals, which can counteract the detrimental effects of T2DM and osteoporosis pathologies. This review describes the polyphenols that can exert protective effects against T2DM and osteoporosis through the modulation of specific molecular markers and pathways. These bioactives could be used as adjuvants, in combination with synthetic drugs, in the future to develop innovative therapeutic strategies for the treatment of T2DM and osteoporosis.

1 September 2020 in Clinical & Translational Metabolism
Verified
Journal Article
Open access
PDF file
GSGianmaria Salvio
Gianmaria Salvio
CGClaudio Gianfelice
Claudio Gianfelice
FFFrancesca Firmani
Francesca Firmani
SLStefano Lunetti
Stefano Lunetti
GBGiancarlo Balercia
Giancarlo Balercia
GGGilberta Giacchetti
Gilberta Giacchetti
Even though inflammatory conditions are known to exert adverse effects on bone metabolism, there are no published data regarding SARS-CoV-2 infection and subsequent fracture risk. We present a brief review of the molecular mechanisms linking inflammatory diseases to increased fracture risk/osteoporosis and of the therapeutic strategies that can prevent bone resorption in patients with inflammatory disease, focusing on the RANK-RANKL system. We also make some considerations on gender differences in infection response and on their implications for survival and for the consequences of COVID-19. Several inflammatory cytokines, especially IL-1, IL-6, and TNF-α, stimulate osteoclast activity, favoring bone resorption through the RANK-RANKL system. Data from the previous SARS-CoV outbreak suggest that the present disease also has the potential to act directly on bone resorption units, although confirmation is clearly needed. Even though the available data are limited, the RANK-RANKL system may provide the best therapeutic target to prevent bone resorption after COVID-19 disease. Vitamin D supplementation in case of deficiency could definitely be beneficial for bone metabolism, as well as for the immune system. Supplementation of vitamin D in case of deficiency could be further advantageous. In COVID-19 patients, it would be useful to measure the bone metabolism markers and vitamin D. Targeting the RANK-RANKL system should be a priority, and denosumab could represent a safe and effective choice. In the near future, every effort should be made to investigate the fracture risk after SARS-CoV-2 infection.

Verified
Journal Article
Open access
PDF file
CGChiara Giordani
Chiara Giordani
Giulia MatacchioneGiulia Matacchione
Giulia Matacchione
AGAngelica Giuliani
Angelica Giuliani
DVDebora Valli
Debora Valli
ESEmanuele-Salvatore Scarpa
Emanuele-Salvatore Scarpa
Maria RippoMaria Rippo
Maria Rippo
During aging, bone marrow mesenchymal stromal cells (MSCs)—the precursors of osteoblasts—undergo cellular senescence, losing their osteogenic potential and acquiring a pro-inflammatory secretory phenotype. These dysfunctions cause bone loss and lead to osteoporosis. Prevention and intervention at an early stage of bone loss are important, and naturally active compounds could represent a valid help in addition to diet. Here, we tested the hypothesis that the combination of two pro-osteogenic factors, namely orthosilicic acid (OA) and vitamin K2 (VK2), and three other anti-inflammatory compounds, namely curcumin (CUR), polydatin (PD) and quercetin (QCT)—that mirror the nutraceutical BlastiMin Complex® (Mivell, Italy)—would be effective in promoting MSC osteogenesis, even of replicative senescent cells (sMSCs), and inhibiting their pro-inflammatory phenotype in vitro. Results showed that when used at non-cytotoxic doses, (i) the association of OA and VK2 promoted MSC differentiation into osteoblasts, even when cultured without other pro-differentiating factors; and (ii) CUR, PD and QCT exerted an anti-inflammatory effect on sMSCs, and also synergized with OA and VK2 in promoting the expression of the pivotal osteogenic marker ALP in these cells. Overall, these data suggest a potential role of using a combination of all of these natural compounds as a supplement to prevent or control the progression of age-related osteoporosis.

5 October 2023 in Antioxidants
Verified
Journal Article
Open access
PDF file
GSGianmaria Salvio
Gianmaria Salvio
ACAlessandro Ciarloni
Alessandro Ciarloni
CGClaudio Gianfelice
Claudio Gianfelice
FLFrancesca Lacchè
Francesca Lacchè
SSSofia Sabatelli
Sofia Sabatelli
GBGiancarlo Balercia
Giancarlo Balercia
Osteoporosis is a condition favored by the postmenopausal decline in estrogen levels and worsened by oxidative stress (OS). Polyphenols are natural compounds abundantly found in fruits and vegetables, and they exert antioxidant and hormonal effects that could be useful in osteoporosis prevention, as suggested by epidemiological studies showing a lower incidence of fractures in individuals consuming polyphenol-rich diets. The aim of our meta-analysis is to evaluate the effects of polyphenols on bone mineral density (BMD, primary endpoint) and bone turnover markers (BTMs, secondary endpoint) in postmenopausal women. Twenty-one randomized control trials (RCTs) were included in our analysis after in-depth search on PubMed, EMBASE, and Scopus databases. We found that supplementation with polyphenols for 3–36 months exerted no statically significant effects on BMD measured at lumbar spine (sMD: 0.21, 95% CI [−0.08 to 0.51], p = 0.16), femoral neck (sMD: 0.16, 95% CI [−0.23 to 0.55], p = 0.42), total hip (sMD: 0.05, 95% CI [−0.14 to 0.24], p = 0.61), and whole body (sMD: −0.12, 95% CI [−0.42 to 0.17], p = 0.41). Subgroup analysis based on treatment duration showed no statistical significance, but a significant effect on lumbar BMD emerged when studies with duration of 24 months or greater were analyzed separately. On the other hand, we found a significantly slight increase in bone-specific alkaline phosphatase (BALP) levels (sMD: 1.27, 95% CI [1.13 to 1.42], p < 0.0001) and a decrease in pyridinoline (PD) levels (sMD: −0.58, 95% CI [−0.77 to −0.39], p < 0.0001). High heterogeneity among studies and unclear risk of bias in one third of the included studies emerged. A subgroup analysis showed similar effects for different duration of treatment and models of dual-energy X-ray absorptiometry (DXA) scanner. More robust evidence is needed before recommending the prescription of polyphenols in clinical practice.

2 March 2022 in Archives of Osteoporosis
Verified
Journal Article
Open access
PDF file
GSGianmaria Salvio
Gianmaria Salvio
CGClaudio Gianfelice
Claudio Gianfelice
FFFrancesca Firmani
Francesca Firmani
SLStefano Lunetti
Stefano Lunetti
RFRossella Ferroni
Rossella Ferroni
GGGilberta Giacchetti
Gilberta Giacchetti
Summary We conducted a survey during the first pandemic wave of coronavirus disease 2019 (COVID-19) on a large group of osteoporotic patients to evaluate the general conditions of osteoporotic patients and the impact of the pandemic on the management of osteoporosis, finding high compliance to treatments and low COVID-19 lethality. Introduction During the first pandemic wave of coronavirus disease 2019 (COVID-19), 209,254 cases were diagnosed in Italy; fatalities were 26,892 and were overwhelmingly older patients. The high prevalence of osteoporosis in this age group suggests a potential relationship between SARS-CoV-2 infection and bone metabolism. Methods In a telephone survey conducted from April to May 2020, patients from the Osteoporosis Center, Clinic of Endocrinology and Metabolic Diseases of Umberto I Hospital (Ancona, Italy), were interviewed to evaluate the general clinical conditions of osteoporotic patients, compliance with osteoporosis medications, COVID-19 prevalence, hospitalization rate, COVID-19 mortality, and lethality. Results Among the 892 patients interviewed, 77.9% were taking osteoporosis treatment and 94.6% vitamin D supplementation as prescribed at the last visit. COVID-19-like symptoms were reported by 5.1%, whereas confirmed cases were 1.2%. A total number of 33 patients had been in hospital and the hospitalization rate of those who had not discontinued vitamin D supplementation was less than 4%. There were eight deaths, two with a concomitant COVID-19 diagnosis. The prevalence of severe osteoporosis was 50% in total COVID-19 patients and 87.5% in deceased COVID-19 patients. The overall COVID-19 mortality was 0.2%; lethality was 20%, lower than the national rate of the same age group. Conclusions This large group of osteoporotic patients showed high compliance and lower COVID-19 lethality compared to patients of the same age. Novel approaches such as telemedicine can provide critical support for the remote follow-up of patients with chronic diseases also in the setting of routine care.

Verified
Journal Article
Open access
PDF file
ESEmanuele-Salvatore Scarpa
Emanuele-Salvatore Scarpa
Stefano AmatoriStefano Amatori
Stefano Amatori
Giovanni CaprioliGiovanni Caprioli
Giovanni Caprioli
Filippo MaggiFilippo Maggi
Filippo Maggi
GMGianluca Moroncini
Gianluca Moroncini
GGGilberta Giacchetti
Gilberta Giacchetti
Obesity is a chronic, multifactorial metabolic disease associated with various factors such as insulin resistance, increased adipogenesis, induction of gluconeogenesis, epigenetic mechanisms, chronic inflammatory state, and oxidative stress. Anti-obesity drugs such as Semaglutide and Tirzepatide are currently used in therapies for obese patients and exert remarkable anti-obesogenic effects, determining weight loss and inhibition of insulin resistance. The impairment of the adipogenesis process and the inhibition of the differentiation of human bone marrow mesenchymal stem cells into adipocytes should also be considered to improve the therapeutic strategies for obesity. Notably, the ability of several flavonoids to inhibit adipogenesis has been described. Flavonoids are the most abundant polyphenols in the human diet and exhibit a wide range of biological properties, including antioxidant and anti-inflammatory effects. Furthermore, many flavonoids can modulate the activity of enzymes involved in epigenetic mechanisms, which play a crucial role in obesity development. The purpose of this review is the identification of those flavonoids able to exert anti-adipogenic and anti-obesity effects in both in vitro and in vivo experimental models, with the aim of combining these natural molecules, as adjuvants, with anti-obesogenic drugs to develop innovative therapeutic approaches for the treatment of obesity pathology.